research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
Search
for
Sort by
Research
90-120 / 566 results 
research Pathomechanisms of Immune-Mediated Alopecia
The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research Janus Kinase (JAK) Inhibitors in Treating Alopecia Areata (AA)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Real-World Experience of Efficacy and Safety of Baricitinib in Korean Patients with Severe Alopecia Areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib treatment for hair loss may worsen acne.
research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib, a hair regrowth treatment, may worsen acne.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research Baricitinib (Olumiant) for Severe Alopecia Areata Treatment Recommendations
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Scarring Hair Follicle Destruction Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis
JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
research A Retrospective Review of Pediatric Alopecia Areata Cases Seen in a Tertiary Institution in Singapore
Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
research Baricitinib as a Treatment for Myasthenia Gravis: A Case Report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research Case Report: Baricitinib Improved Alopecia Areata in a Pediatric Patient with Atopic Dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
research Review of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Upadacitinib for the Treatment of Alopecia Areata – A Case Report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Recovery of Nail Dystrophy: Potential New Therapeutic Indication of Tofacitinib
Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
research Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
More precise, personalized therapies are needed for autoimmune diseases.
research Biomarkers in Alopecia Areata: A Systematic Review and Meta-Analysis
High levels of IL6 and CRP, and low levels of vitamin D, might be indicators of alopecia areata.
research Case Report of Novel Combination of Anthralin and Calcipotriene Leading to Trichologic Response in Alopecia Areata
A new mix of anthralin and calcipotriene might help treat severe hair loss.
research Application of Non-Pharmacologic Therapy in Hair Loss Treatment and Hair Regrowth
Non-drug therapies show promise for hair regrowth but need more research.
research Photobiomodulation for Skin Pigmentation Disorders: A Dual-Function Treatment
Light therapy is effective and safe for treating skin color disorders like vitiligo and dark spots.
research Exosomes Secreted from Adipose-Derived Stem Cells Are a Potential Treatment Agent for Immune-Mediated Alopecia
Exosomes from fat-derived stem cells can potentially improve hair growth and could be a new treatment for immune-related hair loss.
research Mesenchymal Stem Cell Therapy in Alopecia Areata: Visual and Molecular Evidence from a Mouse Model
Mesenchymal Stem Cell therapy shows promise for treating hair loss in Alopecia Areata.